UBS Group’s AgomAb Therapeutics NV AGMB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$572K Buy
51,516
+49,388
+2,321% +$639K ﹤0.01% 6102
2026
Q2
$27.6K Sell
2,128
-4,309
-67% -$48.5K ﹤0.01% 7949
2026
Q1
$67.5K Buy
+6,437
New +$91.2K ﹤0.01% 7207

Other funds holding AGMB

UBS Group's AGMB Position: Q3 2026 in Review

UBS Group increased its AgomAb Therapeutics NV (AGMB) stake by 2,321% in Q3 2026, buying an estimated $639K and bringing the position to 51,516 shares worth $572K. The position accounts for ﹤0.01% of the portfolio, ranked #6102.

UBS Group first reported a position in AGMB in Q1 2026 and has held it in 3 quarters since. 25 funds tracked by Wall St. Rank hold AGMB as of Q3 2026.

  • UBS Group held 51,516 shares of AgomAb Therapeutics NV worth $572K as of Q3 2026.
  • UBS Group bought 49,388 AgomAb Therapeutics NV shares in Q3 2026, an estimated $639K.
  • AgomAb Therapeutics NV made up ﹤0.01% of UBS Group's portfolio in Q3 2026, its #6102 holding.
  • UBS Group first reported a position in AgomAb Therapeutics NV in Q1 2026 and has held it in 3 quarters since.
  • 25 funds tracked by Wall St. Rank held AgomAb Therapeutics NV as of Q3 2026.

Based on UBS Group's 13F filing for Q3 2026, filed 10 Nov 2026.